In preclinical studies, activating ICOS by an agonist is not sufficient to mediate anti-tumor effect, combining blocking inhibitory checkpoints and ICOS agonist mAbs should be considered as a promising strategy for improving efficacy for cancer immunotherapy. Here, ICOS is linked to neoplasm.